Ontario Centres of Excellence (OCE) is building on its partnership with Quebec-based CQDM by bringing additional funding to a novel program dedicated to breakthrough technologies that accelerate drug discovery and development.
With an investment of $500,000, OCE is joining CQDM in expanding the 2014 edition of CQDM’s Explore Program into Ontario. This unique initiative fosters highly innovative and unconventional game-changing biopharmaceutical research. This is the first time this program will be open to researchers in Ontario as well as in Quebec, thanks to this enhanced partnership.
“This is the continuation of the work we have been doing with CQDM in the Ontario-Quebec Life Sciences Corridor,” says Dr. Tom Corr, President and CEO of OCE. “We are delighted to extend our collaboration to CQDM’s farsighted Explore Program, opening it to Ontario-based researchers and SMEs. With CQDM and its partners, we are making it possible to bridge the gap and fund innovative research projects that can potentially be game changers in drug discovery and development.”
The partnership, along with a new venture between CQDM and the Ontario Brain Institute (OBI), was announced at the 2014 Bio International Convention in San Diego on June 23.
“I am pleased that Ontario organizations like OCE and OBI are working with colleagues in Quebec on such important programs,” says Kathleen Wynne, Premier of Ontario. “These are the kinds of strategic partnerships we envisioned when we created the Ontario-Quebec Life Sciences corridor. Developing innovative new technologies in this field will result in positive economic outcomes for both provinces.”
“We are very happy to deepen our collaborations with OCE and OBI in such unique initiatives and bring a true contribution in filling the gaps in innovation in Quebec, Ontario as well as Canada,” adds Diane Gosselin, President and CEO of CQDM. “We are glad to tap into Ontario’s excellence in research and further develop synergies between Quebec and Ontario. Today’s announcement illustrates the value-added of CQDM’s unique business model to support truly innovative translational research.”